From: Impact of immune checkpoint inhibitors (ICIs) therapy on interferon-γ release assay (IGRA) and diagnostic value in non-small cell lung cancer (NSCLC) patients
T-SPOT Counts
Increase
n = 4
No change
n = 12
Decrease
n = 16
P value
Prognosis, n(%)
PD
2(50.0)
8(66.7)
10(62.5)
0.527
DCR
4(33.3)
6(37.5)
Dead
0(0.0)
3(25.0)
4(25.0)
0.837
Survival
4(100.0)
9(75.0)
12(75.0)